Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
CA Rudramurthy BV of Vachana Investments recommmends selling Glenmark Pharma as the stock may test Rs 730.
Vijay Chopra of enochventures.com is of the view that one may exit Marksans Pharma.
Deven Choksey of KRChoksey Invst Managers likes Sun Pharmaceutical Industries, Cipla and Glenmark Pharma from the pharma space.
Sudarshan Sukhani of s2analytics.com recommends shorting Bharat Electronics Limited and NMDC.
Prakash Gaba of prakashgaba.com recommends going long in Dish TV and advises selling PTC India.
Sudarshan Sukhani of s2analytics.com is of the view that one may sell Glenmark Pharma.
Sudarshan Sukhani of s2analytics.com recommends selling pharma stocks and advises buying Hero Motocorp and Power Grid.
Prakash Gaba of prakashgaba.com is of the view that one may short Punjab National Bank and Lupin and feels that Britannia Industries may test Rs 2,550.
Deven Choksey of KRChoksey Investment Managers likes Glenmark Pharma and Sun Pharma.
Ashwani Gujral of ashwanigujral.com recommends buying Ashok Leyland and Aurobindo Pharma.
Ashwani Gujral of ashwanigujral.com recommends buying Glenmark Pharma, Jubilant Foodworks and LIC Housing Finance.
Ashwani Gujral of ashwanigujral.com recommends selling Marico and NCC and advises buying Tata Steel.
Ashwani Gujral of ashwanigujral.com recommends selling Glenmark Pharma and DHFL and advises buying Tech Mahindra.
Ashwani Gujral of ashwanigujral.com is of the view that one may prefer Aurobindo Pharma, Ajanta Pharma and Torrent Pharma and likes Glenmark Pharma.
SP Tulsian of sptulsian.com recommends buying Lupin, Glenmark Pharma and Wockhardt.
Sudarshan Sukhani of s2analytics.com recommends buying Bata India and advises selling Glenmark and SAIL.
SP Tulsian of sptulsian.com likes Aurobindo Pharma and Glenmark Pharma.
Sudarshan Sukhani of s2analytics.com is of the view that one may buy Asian Paints.
Gaurav Ratnaparkhi of Sharekhan advises buying Federal Bank with a target of Rs 49.20.
SP Tulsian of sptulsian.com has a positive view on Aurobindo Pharma and feels that one can look at Glenmark Pharma and Lupin.
Gaurav Ratnaparkhi of Sharekhan suggests buying Bharat Forge with a target of Rs 875.
Manas Jaiswal of manasjaiswal.com suggests selling Glenmark Pharma with a target of Rs 700.
Ajay Bodke of Prabhudas Lilladher feels that Glenmark Pharma may move to Rs 1186.
SP Tulsian of sptulsian.com is of the view that JSW Steel may test Rs 1000.
Abhishek Sharma, Pharma Analyst at IIFL recommends buying Glenmark Pharma and likes Lupin and Dr Reddy's Labs.